GlassScriptPhysician profile
Van Martin Teague
NPI 1336182823
$6,796.79
in general payments reported to CMS, 2019-2025
27 companies · $1,642 in 2025
The $1,642 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $988 · 2020: $350 · 2021: $930 · 2022: $801 · 2023: $1,386 · 2024: $699 · 2025: $1,642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,727.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,079.20 | 2019-2025 | Clareon, Hydrus Microstent, Total30 |
| Sun Pharmaceutical Industries INC. | $1,022.50 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $645.91 | 2022-2025 | Infuse, Miebo, Xiidra |
| Coopervision INC. | $543.01 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $530.42 | 2019-2021 | |
| Allergan, INC. | $324.18 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $306.92 | 2024-2025 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $289.69 | 2019-2024 | Acuvue |
| Dompe US, INC. | $271.65 | 2021-2025 | Oxervate |
| Mallinckrodt Hospital Products INC. | $203.97 | 2021-2025 | Acthar |
| Kala Pharmaceuticals, INC. | $203.12 | 2019-2022 | |
| Biotissue Holdings INC. | $190.15 | 2025 | |
| Shire North American Group INC | $146.64 | 2019 | |
| Oyster Point Pharma, INC. | $119.93 | 2023-2025 | Tyrvaya |
| Ani Pharmaceuticals, INC. | $109.70 | 2023-2025 | Purified Cortrophin Gel |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $108.59 | 2024-2025 | Vevye |
| Novartis Pharmaceuticals Corporation | $108.29 | 2019-2023 | |
| Amgen INC. | $107.54 | 2024-2025 | Tepezza |
| Abbvie INC. | $103.99 | 2023 | Lumigan |
| Glaukos Corporation | $97.26 | 2023-2025 | Photrexa Viscous and Photrexa |
| Aerie Pharmaceuticals, INC. | $74.35 | 2019-2021 | |
| Optos, INC. | $61.28 | 2019 | |
| Horizon Therapeutics Plc | $37.61 | 2023 | Tepezza |
| Alimera Sciences, INC. | $32.77 | 2024 | Iluvien, Yutiq |
| Thea Pharma INC. | $29.67 | 2022-2023 | |
| Johnson & Johnson Surgical Vision, INC. | $26.28 | 2019-2021 | |
| Sight Sciences, INC. | $22.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Van Teague listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.